July 08, 2019
2 min watch
Save

VIDEO: Neurotech advances cell therapies for macular telangiectasia, glaucoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEWPORT BEACH, Calif. — At OCTANe’s Ophthalmology Technology Summit, Richard Small, CPA, CEO of Neurotech Pharmaceuticals, discusses the company’s pipeline, including encapsulated cell therapy, or ECT, for macular telangiectasia.